Table 4.

Clinical trials of BNCT in other cancer

Time	Cancer Type	Trial ID	Phase	Case	Drug	Maximum Dose of Radiation	Outcomes (SD1/PFS2/CR3)	Citation
Registered Clinical Trials
1997-2006	Metastatic Melanoma	NCT00085059	II	4	100 mg BSH4/kg	60.0 muSV5/h	N/A	[76]
2002-2005	Metastatic Melanoma	NCT00039572	I/II	2	350 mg BPA6/kg	N/A	N/A	[20,78]
2003-2007	Metastatic Hepatoma	NCT00062348	I	6	600 mg BSH/kg	/	N/A	[79,80]
					200 mg BPA/kg
2019-2020	AS7	jRCTs051180217	II	2	BPA##	N/A	N/A	[90]
2019-2020	rBC8	jRCTs051180219	II	1	BPA##	N/A	N/A	[91]
2022-	rBC	jRCTs031220371	0	5#	BPA##	N/A	N/A	[92]
Investigator-initiated Clinical Trials
2005	HCC9	N/A	I/II	1	1 g BSH/body	2.0 Gy-Eq10	SD time: 1 month	[84]
					250 mg BPA/kg
2005-2006	MPM11/MSSpCC12	N/A	I/II	2	250-500 mg BPA/kg	44.7 Gy-Eq	PFS time: 3-6 months	[81]
2005-2014	EMPD13	N/A	I/II	4	200 mg BPA/kg	25.0 Gy-Eq	6m CR: 100%	[86]
2006	MPM	N/A	I/II	3	500 mg BPA/kg	39.5 Gy-Eq	N/A	[82]
2009	MPM/Hepatoma	N/A	I/II	10	BPA##	5.0 Gy-Eq	N/A	[83]
2011	HCC	N/A	I/II	1	300 mg BSH/body	5.0 Gy-Eq	SD time: 3 months	[85]
2012	EMPD	N/A	I/II	2	BPA##	N/A	1y CR: 100%	[87]
2014	Sarcomas	N/A	I/II	1	500 mg BPA/kg	13.0 Gy-Eq	N/A	[88]
2015	MPNST14	N/A	I/II	1	500 mg BPA/kg	24.3 Gy-Eq	SD time: 2 years	[89]

¹SD: stable disease;

²PFS: progression-free survival;

³CR: complete remission;

⁴BSH: sodium borocaptate;

⁵uSV: microsievert;

⁶BPA: boronophenylalanine;

⁷AS: angiosarcoma;

⁸rBC: refractory breast cancer;

⁹HCC: hepatocellular carcinoma;

¹⁰Gy-Eq: Gray Equivalent;

¹¹MPM: malignant pleural mesothelioma;

¹²MSSpCC: malignant short spindle cell carcinoma;

¹³EMPD: Extramammary Paget’s Disease;

¹⁴MPNST: malignant peripheral nerve sheath tumor.

^#Number of patients panned to recruit in the registered information for ongoing trials or trials not yet updated after its predicted completion date.

^##The drug dosage is not reflected in the literature.